Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-PLANET: Camrelizumab + Chemoradiation for Gastric Cancer
NCT03631615Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2018
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in gastric adenocarcinoma, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Pathological Complete Remission at 5 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03631615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631615.